3rd Quarter - Report

NOVO NORDISK INC. for NOVO NORDISK INC.

Firm
Client
Income
—
Expenses
$620,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

P.L. 114-26 Bipartisan Congressional Trade Priorities and Accountability Act of 2015; EU/US Transatlantic Trade and Investment Partnership (TTIP) (intellectual property, regulatory harmonization)

Contacted: Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); SENATE; Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Copyright/Patent/Trademark CPT

H.R. 9 Innovation Act and and S. 1137 PATENT Act (patent litigation and assertion); S.1890 and H.R.3326 Defend Trade Secrets Act of 2015

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); SENATE; Health Resources & Services Administration (HRSA); Executive Office of the President (EOP); Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH)

Bills named: H.R. 9 (114th), H.R. 3326 (114th), S. 1890 (114th), S. 1137 (114th)

Health Issues HCR

National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes), AHRQ and USPSTF diabetes screening standards; diabetes issues in Healthy People 2020 and the Office of Disease Prevention and Health Promotion (ODPHP); H.R. 1074 and S. 539 National Diabetes Clinical Care Commission Act of 2013; P.L. 114-10, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) for Special Diabetes Program, CHIP, and childhood obesity; S. 84 and H.R. 3658 Gestational Diabetes Act of 2015; H.R. 1190 and S. 141 Protecting Seniors' Access to Medicare Act of 2015 (IPAB repeal); H.R. 2651 Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2015 (EDDPAC); cost of diabetes generally; S. 320 and H.R. 744 Medical Innovation Act of 2015; S. 2023 and H.R. 3513 Prescription Drug Affordability Act of 2015; H.R. 3742, Access to Marketplace Insurance Act and general allowance for certain third party payments of cost sharing.

Contacted: Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); SENATE; HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1190 (114th), H.R. 744 (114th), H.R. 3513 (114th), S. 84 (114th), S. 141 (114th), H.R. 1074 (114th), S. 2023 (114th), H.R. 3742 (114th), S. 539 (114th), H.R. 2651 (114th), H.R. 3658 (114th), S. 320 (114th)

Medicare/Medicaid MMM

Issues related to Medicare Part D, Special Diabetes Program, CHIP, and childhood obesity in P.L. 114-10 Medicare Access and CHIP Reauthorization Act of 2015 (MACRA); H.R. 2102 and S.1131 Medicare Diabetes Prevention Act; H.R. 2404 and S. 1509 Treat and Reduce Obesity Act; Issues related to medical nutrition therapy services to such beneficiaries with pre-diabetes or with risk factors for developing type 2 diabetes H.R. 1686 Medical Nutrition Therapy 2015; issues related to patient diabetes education in H.R. 1726 Access to Quality Diabetes Education Act of 2015; Continuous Glucose Monitoring (CGM); Medicare diabetes screening generally; H.R. 1021 Protecting the Integrity of Medicare Act (PIMA) of 2015; H.R.2005 and S. 1083 Medicare Drug Savings Act of 2015; Physician Quality and Reporting System (PQRS)

Contacted: Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Health Resources & Services Administration (HRSA)

Bills named: S. 1083 (114th), H.R. 1686 (114th), H.R. 1726 (114th), S. 1509 (114th), H.R. 2404 (114th), H.R. 2102 (114th), H.R. 2005 (114th), H.R. 1021 (114th), S. 1131 (114th)

Budget/Appropriations BUD

Issues related to National Diabetes Prevention Program in H.R. 3020 and S.1695 FY16 Labor/HHS/Education Appropriations and P.L. 113-235 FY15 Consolidated and Continuing Appropriations; Issues related to Medicare Part D, FDA, patents, and federal procurement in S.Con.Res.11 FY16 Senate Budget Resolution and H.Con.Res.27 House Budget Resolution; H.R. 3660 Preventive Health Savings Act

Contacted: Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); SENATE; HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 3660 (114th), S.Con.Res. 11 (114th), S. 1695 (114th), H.R. 3020 (114th), H.Con.Res. 27 (114th)

Pharmacy PHA

P.L. 113-54 Drug Quality and Security Act (track and trace supply chain provisions); issues regarding biosimilars; issues regarding 340B; H.R.6 21st Century Cures Act; FDA in HR 3049 FY16 Agriculture Appropriations

Contacted: HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); SENATE; Natl Institutes of Health (NIH); Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 3049 (114th), H.R. 6 (114th)

Taxation/Internal Revenue Code TAX

H.R. 880 R&D tax credit; corporate tax inversion generally and in amendments to S.Con.Res.11 FY16 Senate Budget Resolution and S. 1376 FY16 National Defense Authorization Act; interest deductibility IRC 163(j)

Contacted: Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); SENATE; Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); Executive Office of the President (EOP)

Bills named: S.Con.Res. 11 (114th), H.R. 880 (114th), S. 1376 (114th)

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.